Abstract |
1. To characterize the anti-arrhythmic properties of a new calcium antagonist, monatepil [corrected], AJ-2615, the preventive effects of AJ-2615 were compared with those of the existing calcium antagonists, diltiazem and verapamil, in experimental models of arrhythmia. 2. AJ-2615 (0.1-3.0 mg/kg, i.v.) suppressed ventricular arrhythmias induced by adrenaline (10 micrograms/kg, i.v.) in rats. AJ-2615 (0.1 mg/kg per min for 2 min, i.v.) also suppressed atrial tachycardia induced by aconitine (0.01% aconitine solution) in rats. 3. In these activities, AJ-2615 was comparable to or more potent than diltiazem and verapamil which are widely used for the treatment of arrhythmia. 4. In pro-arrhythmic activity, AJ-2615 was less potent than diltiazem and verapamil. 5. These results suggest that AJ-2615 would be a safer anti-arrhythmic agent, with less proarrhythmic liability than diltiazem and verapamil.
|
Authors | T Yamamoto, K Hosoki, T Karasawa |
Journal | Clinical and experimental pharmacology & physiology
(Clin Exp Pharmacol Physiol)
1993 Jul-Aug
Vol. 20
Issue 7-8
Pg. 497-500
ISSN: 0305-1870 [Print] Australia |
PMID | 8403530
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Calcium Channel Blockers
- Dibenzothiepins
- Piperazines
- Verapamil
- Diltiazem
- monatepil
- Aconitine
- Epinephrine
|
Topics |
- Aconitine
(toxicity)
- Animals
- Arrhythmias, Cardiac
(chemically induced, drug therapy)
- Calcium Channel Blockers
(administration & dosage, therapeutic use, toxicity)
- Dibenzothiepins
(administration & dosage, therapeutic use, toxicity)
- Diltiazem
(administration & dosage, therapeutic use, toxicity)
- Disease Models, Animal
- Epinephrine
(toxicity)
- Injections, Intravenous
- Male
- Piperazines
(administration & dosage, therapeutic use, toxicity)
- Rats
- Rats, Wistar
- Tachycardia
(drug therapy, prevention & control)
- Verapamil
(administration & dosage, therapeutic use, toxicity)
|